HOOKIPA shareholders approve asset sale to Gilead and company dissolution

HOOKIPA Pharma Inc.

Asset sale to Gilead Sciences approved: 5,063,462 for, 239,595 against, 1,502 abstain.
Plan of liquidation and dissolution approved: 4,969,875 for, 329,803 against, 4,881 abstain.
Adjournment proposal approved: 5,110,153 for, 191,383 against, 3,023 abstain.
Special meeting held July 29, 2025; 54.13% of outstanding shares voted.
Company will proceed with dissolution following asset sale closing.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.